Delayed graft function in kidney transplant recipients: risk factors and short-term outcome

Iglesias-Márquez, R.A; Santiago-Delpín, Eduardo A.; Zayas, Emilio López-Barajas; Gonzalez-Caraballo, Z.; Morales-Otero, L.

doi:10.1016/s0041-1345(01)02796-8

Cited by 3 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As shown in our results, many biopsies were done during the first week (about 50%), a critical period for ACR but also for the acute allograft ischemic injury. This phenomenon affects mostly the medulla and is frequently seen in kidneys from deceased donors [15,16]. Morphologically, it is characterized by acute tubular necrosis and by dilatation of the medullary vasa recta, with leukocyte endothelial adhesion that discreetly spill over to the interstitium [17][18][19].…”

Section: Discussionmentioning

confidence: 99%

Medullary nephritis in the diagnosis of acute cellular rejection

Visoná

Sementilli

Kuschnaroff

et al. 2015

Pathology - Research and Practice

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Medullary nephritis in the diagnosis of acute cellular rejection

Visoná

Sementilli

Kuschnaroff

et al. 2015

Pathology - Research and Practice

View full text Add to dashboard Cite

Profiling risk for acute rejection in kidney transplantation: recipient age is a robust risk factor

et al. 2016

View full text Add to dashboard Cite

Careful management of immunosuppression is paramount to prevent acute rejection in kidney transplantation. We studied a cohort of 139,875 kidney transplant recipients from the Organ Procurement and Transplantation Network (OPTN) database between 2002 and 2013. We confirmed the analysis with a cohort of 35,277 who received thymoglobulin induction with tacrolimus maintenance, and a third cohort of 12,161 recipients who received basiliximab induction with tacrolimus maintenance. We performed multivariate logistic regression analyses on data from all three cohorts and identified independent risk factors for treated acute rejection at 1 year. Recipient age was a robust risk factor for rejection in all three cohorts in a dose response pattern. Young age (18-25 years) was among the strongest risk factors for rejection in all three cohorts; thymoglobulin cohort: OR 1.87 (1.59-2.19); basiliximab cohort: OR 2.41 (1.89-3.05); and inclusive cohort: OR 1.97 (1.83-2.12). The opposite was true for old age (65-69 years); thymoglobulin cohort: OR 0.69 (0.59-0.81); basiliximab cohort: OR 0.77 (0.62-0.96); and inclusive cohort: OR 0.75 (0.70-0.80). This study is unique because it is the largest and most comprehensive multivariate analysis that demonstrates recipient age is a robust risk factor for acute rejection in an inverse dose response pattern.

show abstract